Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ORCHID PHARMA LTD Sep-13 |
MYLAN Dec-18 |
ORCHID PHARMA LTD/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 194 | 3,366 | - | |
Low | Rs | 35 | 1,853 | - | |
Sales per share (Unadj.) | Rs | 276.5 | 1,548.7 | - | |
Earnings per share (Unadj.) | Rs | -79.2 | 42.1 | - | |
Cash flow per share (Unadj.) | Rs | -43.5 | 332.0 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 53.9 | 1,675.5 | - | |
Shares outstanding (eoy) | m | 70.45 | 514.50 | - | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 0.4 | 1.7 | 24.6% | |
Avg P/E ratio | x | -1.4 | 62.0 | -2.3% | |
P/CF ratio (eoy) | x | -2.6 | 7.9 | -33.5% | |
Price / Book Value ratio | x | 2.1 | 1.6 | 136.3% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 8,067 | 1,342,433 | 0.6% | |
No. of employees | `000 | 2.8 | 35.0 | 8.0% | |
Total wages/salary | Rs m | 2,527 | 0 | - | |
Avg. sales/employee | Rs Th | 6,956.1 | 22,766.6 | 30.6% | |
Avg. wages/employee | Rs Th | 902.5 | 0 | - | |
Avg. net profit/employee | Rs Th | -1,993.0 | 618.2 | -322.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 19,477 | 796,831 | 2.4% | |
Other income | Rs m | 407 | 0 | - | |
Total revenues | Rs m | 19,884 | 796,831 | 2.5% | |
Gross profit | Rs m | 1,103 | 206,190 | 0.5% | |
Depreciation | Rs m | 2,519 | 149,198 | 1.7% | |
Interest | Rs m | 5,227 | 38,325 | 13.6% | |
Profit before tax | Rs m | -6,236 | 18,667 | -33.4% | |
Minority Interest | Rs m | 20 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 511 | 0 | - | |
Tax | Rs m | -125 | -2,970 | 4.2% | |
Profit after tax | Rs m | -5,580 | 21,637 | -25.8% | |
Gross profit margin | % | 5.7 | 25.9 | 21.9% | |
Effective tax rate | % | 2.0 | -15.9 | -12.6% | |
Net profit margin | % | -28.7 | 2.7 | -1,055.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,014 | 444,950 | 2.5% | |
Current liabilities | Rs m | 32,060 | 324,417 | 9.9% | |
Net working cap to sales | % | -108.1 | 15.1 | -714.4% | |
Current ratio | x | 0.3 | 1.4 | 25.0% | |
Inventory Days | Days | 95 | 84 | 113.5% | |
Debtors Days | Days | 34 | 93 | 36.0% | |
Net fixed assets | Rs m | 29,440 | 154,572 | 19.0% | |
Share capital | Rs m | 705 | 424 | 166.1% | |
Net worth | Rs m | 3,800 | 862,026 | 0.4% | |
Long term debt | Rs m | 9,018 | 930,402 | 1.0% | |
Total assets | Rs m | 46,510 | 2,312,288 | 2.0% | |
Interest coverage | x | -0.2 | 1.5 | -13.0% | |
Debt to equity ratio | x | 2.4 | 1.1 | 219.9% | |
Sales to assets ratio | x | 0.4 | 0.3 | 121.5% | |
Return on assets | % | -0.8 | 2.6 | -29.3% | |
Return on equity | % | -146.9 | 2.5 | -5,850.6% | |
Return on capital | % | -3.7 | 3.2 | -117.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,682 | 165,582 | 1.0% | |
From Investments | Rs m | -9,860 | -85,587 | 11.5% | |
From Financial Activity | Rs m | 6,644 | -77,138 | -8.6% | |
Net Cashflow | Rs m | -1,535 | 1,372 | -111.9% |
Compare ORCHID PHARMA LTD With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ORCHID PHARMA LTD With: NOVARTIS SANOFI INDIA DIVIS LABORATORIES ABBOTT INDIA SHASUN PHARMA
| |
Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.2% while the Hang Seng is up 2.1%.
For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsWhat to do after every trade.
What we can learn from one of the greatest traders to have ever lived.
This corner of the market could provide more returns than blue chips in 2020.
Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
2019 will be remembered as the year of great money-making IPOs...
More
| |